Canagliflozin - CAS# 842133-18-0 Compound 1 inhibits growth hormone

inhibits growth hormone

Chemical Name: 1-{4-[2-(benzyloxy)-4-fluorophenyl]-5-[(1E)-prop-1-en-1-yl]-2

McDonnell DP

suggestive of secondary transcriptional effects and transcription of BRD4 and BRD3 are unaffected

2(3):e00269

Canagliflozin - CAS# 842133-18-0 Compound 1 inhibits growth hormoneCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the